85 WELLS AVENUE, NEWTON, MA
Other Events
Investor Presentation
News, Material Contracts
Submission of Matters to a Vote of Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Closes Financing Transactions with Lenders
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
SC TO-I
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer